Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$83.98 -1.25%

-$1.03 today

Market cap
$4.73B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.84M

Average 0.82M

DNTH Total Debt

Short-term and long-term borrowings combined.

Dianthus Therapeutics, Inc.NASDAQ: DNTH

Total Debt · Q2 FY2026 · quarter ended Jun 2026

Total debt falls 3.2% from a year ago

Total debt stood at $1.29M at the end of Q2 FY2026, down 3.2% from a year earlier and down 5.6% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.

Context

  • Total debt amounted to 0.1% of total assets at the end of Q2 FY2026, down 0.3 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -3.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.29M-5.6% QoQ
Last fiscal yearDec 2025
$1.39M-7.0% YoY
Year agoJun 2025
$1.33M-3.2% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.2%——
1 year-7.0%——
3-year CAGR+20.7%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
1.39M USD
Year-over-year change
-7.0%

Total Debt vs competitors

How DNTH compares with its peers on the latest reported figures

  • DNTH's Jun 2026 total debt of $1.29M is the 8th highest of the 10 companies compared; the peer median is $11.86M.
  • Its year-over-year change of -3.2% is the 5th highest of 9, against a peer median of -4.5%.
  • Total debt amounts to 0.1% of total assets for DNTH, versus a peer median of 9.7%.
DNTH Competitors Peer median
Total Debt for DNTH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$277.36M +1680.8%-10.1%84.1%
MLTXMoonLake ImmunotherapeuticsMar 2026$100.8M +33.3%+544.7%25.2%
VERAVera Therapeutics, Inc.Jun 2026$75.23M -3.0%+35.2%14.1%
ALMSAlumis Inc. Common StockJun 2026$36.43M -6.1%+174.8%6.5%
RNACCartesian Therapeutics, Inc.Mar 2026$11.86M -15.7%-30.6%4.1%
QTTBQ32 Bio Inc.Mar 2026$10.99M -41.5%-30.0%17.3%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$10.26M -26.7%-17.4%9.7%
DNTHDianthus Therapeutics, Inc.Jun 2026$1.29M -3.2%+20.7%0.1%
CNTBConnect Biopharma Holdings LimitedDec 2025$690K +287.6%+17.0%1.2%
IMVTImmunovant, Inc.Sep 2026$0 —-61.1%0.0%
Peer median (excluding DNTH) $11.86M-4.5%-10.1%9.7%

Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents131.65M15.37M132.33M22.79M51.09M
Short-term Investments45.28M60.13M41.39M252.45M353.21M
Net Receivables05.64M478K807K102K
Inventory00000
Other Current Assets3.77M53K504K355K5.04M
Total Current Assets180.69M82.03M177.45M280.9M409.44M
Property, Plant & Equipment (Net)7.46M956K800K1.75M1.63M
Goodwill00000
Intangible Assets00000
Long-term Investments1.78M0081.73M110.14M
Tax Assets00000
Other Non-current Assets0121K1.15M9.63M9.72M
Total Non-current Assets9.24M1.08M1.95M93.1M121.48M
Total Assets189.93M83.11M179.41M374.01M530.92M
Account Payables3.04M1.17M2.61M4.58M9.73M
Short-term Debt00000
Tax Payables00000
Deferred Revenue0100K100K479K1.19M
Other Current Liabilities4.48M2.08M5.36M5.15M9.52M
Total Current Liabilities10.86M8.23M9.63M18.45M30.73M
Long-term Debt00001.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0791K736K1.91M5.77M
Other Non-current Liabilities6.4M0000
Total Non-current Liabilities6.4M1.23M904K3.08M6.79M
Total Liabilities17.26M9.45M10.54M21.53M37.52M
Common Stock59K015K31K43K
Retained Earnings(325.57M)(45.87M)(89.42M)(174.39M)(336.73M)
Accumulated OCI(30K)(161K)47K106K489K
Other Stockholders Equity00000
Minority Interest00000
Total Equity172.67M73.66M168.87M352.48M493.4M
Total Debt0788K585K1.49M1.39M
Net Debt(131.65M)(14.58M)(131.74M)(21.3M)(49.7M)

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Intrinsic Alpha fair value

Locked

Current Price

$83.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.